Loading…
Chinese healthcare group operating private hospitals, having pivoted from its earlier industrial business into hospital ownership.
Chinese healthcare group operating private hospitals, having pivoted from its earlier industrial business into hospital ownership.
In one line: A small Chinese private-hospital operator.
Moat: none (regulatory licence). Hospital operating licences are regulated, but the group lacks a distinctive specialty franchise.
Headquarters: China · Employees: 9,112
Size New Journey Health Technology Group Co., Ltd.Class A (002219.SZ) is a China Health Care company (Pharmaceuticals: Other) with a market value of $999M, the 2299th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥1.93 on 6 Nov 2026.
Performance Over six months the shares fell 16.4%, against -14.9% for the median peer and -16.4% for the China market (cap-weighted) — 10th lowest of 21 in its peer set.
Growth Revenue fell 13.7% over the last twelve months (peer median +7.8%); the operating margin is 8.3% (peer median 15.1%).
Valuation It trades at 193.0× forward earnings against a peer median of 18.6× (most expensive of 16).
Capital Return on invested capital runs 1.5 points above its cost of capital (5.8% WACC).
Next results Next results expected around 23 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥2.91B | CN¥3.05B | CN¥3.79B | CN¥3.91B | CN¥3.16B |
| Revenue growth | — | -20% | -3% | +24% | — |
| Gross profit | CN¥966M | CN¥798M | CN¥1.08B | CN¥1.08B | CN¥927M |
| EBITDA | n/a | CN¥429M | CN¥520M | CN¥402M | CN¥440M |
| Net income | CN¥70.5M | CN¥30.9M | CN¥115M | CN¥29.0M | CN¥156M |
| Free cash flow | -CN¥14.3M | CN¥36.8M | CN¥131M | CN¥112M | CN¥47.0M |
| Capital expenditure | CN¥201M | CN¥257M | CN¥307M | CN¥210M | CN¥222M |
| Total debt | CN¥2.38B | CN¥2.48B | CN¥2.39B | CN¥2.44B | CN¥1.93B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| New Journey Health Technology Group Co., Ltd.Class A 002219.SZ | $999M | -16% | -14% | 8% | 193.0× | n/a |
| Aier Eye Hospital 300015.SZ | $12.5B | -16% | +5% | 21% | 29.5× | 11.7% |
| China Resources Medical 1515.HK | $415M | -12% | 0% | 6% | 5.7× | -7.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002219.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -5.4% | -4.8% | 10th lowest of 21 |
| 6-month return | -16.4% | -14.9% | 10th lowest of 21 |
| Distance from 52-week high | -35.0% | -33.6% | 10th lowest of 21 |
| Revenue growth (TTM) | -13.7% | +7.8% | 4th lowest of 20 |
| Operating margin | 8.3% | 15.1% | 7th lowest of 19 |
| Forward P/E | 193.0× | 18.6× | most expensive of 16 |
| ROIC minus cost of capital | +1.5 pp | +2.0 pp | 9th lowest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| New Journey Health Technology Group Co., Ltd.Class A 002219.SZ | China | $999M | -16% | -14% | 8% | 193.0× | n/a | n/a |
| Applied Nutrition APN.L | United Kingdom | $1.01B | +42% | +24% | n/a | 24.2× | n/a | n/a |
| Sihuan Pharmaceutical 0460.HK | Hong Kong | $952M | -35% | +30% | 15% | 9.7× | n/a | n/a |
| Shandong Xinhua Pharmaceutical 000756.SZ | China | $1.09B | -10% | -5% | 4% | 18.3× | 1.5% | +7.9% |
| TSI 603262.SS | China | $909M | -41% | +3% | 14% | 51.5× | 25.8% | +13.4% |
| HBM 2142.HK | Hong Kong | $1.18B | -23% | +55% | 44% | 12.4× | 14.1% | +62.3% |
| PharmaNutra PHN.MI | Italy | $808M | -18% | +18% | 21% | 29.6× | 4.0% | +18.5% |
| Tianjin Tianyao Pharmaceuticals 600488.SS | China | $801M | -14% | -12% | 3% | n/a | 3.6% | -1.3% |
| BioGaia BIOG-B.ST | Sweden | $1.26B | -7% | +13% | 28% | 30.1× | 0.9% | +15.5% |
| Sirio Pharma 300791.SZ | China | $790M | -12% | -9% | 1% | 16.9× | 14.7% | +15.6% |
| Pharma Mar PHM.MC | Spain | $1.30B | -33% | +32% | 19% | 37.7× | 11.4% | -3.9% |
| Shanghai Kaibao Pharmaceutical 300039.SZ | China | $756M | -17% | -14% | 22% | n/a | 1.8% | +4.8% |
| Cronos CRON.TO | Canada | $1.34B | +45% | +36% | -2% | 15.6× | 2.1% | +26.7% |
| Jamieson Wellness JWEL.TO | Canada | $1.35B | +35% | +15% | 15% | 21.2× | 11.0% | +15.3% |
| China Shineway Pharmaceutical 2877.HK | Hong Kong | $719M | -21% | -18% | 25% | 7.2× | n/a | n/a |
| Brother Enterprises 002562.SZ | China | $716M | -28% | +8% | 4% | n/a | 4.9% | +13.5% |
| Shanxi Zhendong Pharmaceutical 300158.SZ | China | $713M | -16% | -28% | -25% | n/a | n/a | n/a |
| Sudeep Pharma SUDEEPPHRM.NS | India | $1.41B | +75% | +27% | 33% | 67.7× | n/a | n/a |
| ArriVent BioPharma AVBP | United States | $673M | -54% | n/a | n/a | n/a | n/a | n/a |
| Guilin Sanjin Pharmaceutical 002275.SZ | China | $1.53B | +27% | -3% | 24% | 18.6× | -2.2% | +5.5% |
| Bora Pharmaceuticals 6472.TW | Taiwan | $1.55B | -2% | -6% | 15% | 14.2× | 4.5% | +60.2% |